Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Loree, Jonathan M.
Topham, James T.
Kennecke, Hagen Fritz
Feilotter, Harriet
Lee, Young S.
Virk, Shakeel
Kopetz, Scott
Duose, Dzifa Yawa
Manyam, Ganiraju C.
Morris, Jeffrey S.
Maru, Dipen M.
Renouf, Daniel
Jonker, Derek J.
Tu, Dongsheng
O'Callaghan, Christopher J.
Chen, Eric Xueyu
机构：
[1] Genome Sci Ctr, Vancouver, BC, Canada
[2] Providence Canc Inst, Portland, OR USA
[3] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada
[4] AstraZeneca, Translat Med, Gaithersburg, MD USA
[5] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA
[8] Univ Penn, Philadelphia, PA USA
[9] MD Anderson Canc Ctr, Houston, TX USA
[10] Univ British Columbia, Vancouver, BC, Canada
[11] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[12] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3551
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Efficacy and safety of fruquintinib (F) plus best supportive care (BSC) vs placebo (P) plus BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
    Kotani, D.
    Yoshino, T.
    Paulson, A. S.
    Masuishi, T.
    Hochster, H.
    Krauss, J.
    Sunakawa, Y.
    Takashima, A.
    Yamazaki, K.
    Kawakami, H.
    Nishina, T.
    Komatsu, Y.
    Esaki, T.
    Eng, C.
    Dasari, N. A.
    Yu, Z.
    Chen, L.
    Yang, T.
    Schelman, W.
    Satoh, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1506 - S1507
  • [12] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies
    Hofheinz, R.
    Grothey, A.
    Sobrero, A. F.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. -J
    Yoshino, T.
    Cihon, F.
    Strauss, U. P.
    Van Cutsem, E.
    ONKOLOGIE, 2012, 35 : 255 - 255
  • [13] Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial
    Stintzing, Sebastian
    Tabernero, Josep
    Satoh, Taroh
    Dasari, Arvind
    Lonardi, Sara
    Eng, Cathy
    Garcia-Carbonero, Rocio
    Elez, Elena
    Yoshino, Takayuki
    Sobrero, Alberto F.
    Yao, James C.
    Kasper, Stefan
    Arnold, Dirk
    Basic, Edin
    Granold, Matthias
    Petschulies, Marco
    Wu, Liwen
    Chen, Lucy F.
    Yang, Zhao
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [14] Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial
    Stintzing, Sebastian
    Tabernero, Josep
    Satoh, Taroh
    Dasari, Arvind
    Lonardi, Sara
    Eng, Cathy
    Garcia-Carbonero, Rocio
    Elez, Elena
    Yoshino, Takayuki
    Sobrero, Alberto F.
    Yao, James C.
    Kasper, Stefan
    Arnold, Dirk
    Basic, Edin
    Granold, Matthias
    Petschulies, Marco
    Wu, Liwen
    Chen, Lucy
    Yang, Zhao
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 116 - 116
  • [15] Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO.26 trial
    Ma, Lucy Xiaolu
    Titmuss, Emma
    Jonker, Derek J.
    Kennecke, Hagen Fritz
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aubin, Francine
    Koski, Sheryl L.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Loree, Jonathan M.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [16] Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) plus best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2
    Lonardi, Sara
    Dasari, Arvind
    Garcia-Carbonero, Rocio
    Yoshino, Takayuki
    Garcia-Alfonso, Pilar
    Kocsis, Judit
    Cremolini, Chiara
    Ghiringhelli, Francois
    Shergill, Ardaman
    Hochster, Howard S.
    Ducreux, Michel
    Arnold, Dirk
    Sundaresan, Varsha
    Kasar, Siddha
    Pina, Adela
    Yu, Ziji
    Schelman, William R.
    Chen, Lucy
    Tabernero, Josep
    CANCER RESEARCH, 2024, 84 (06)
  • [17] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
    Cunningham, D
    Pyrhönen, S
    James, RD
    Punt, CJA
    Hickish, TF
    Heikkila, R
    Johannesen, TB
    Starkhammar, H
    Topham, CA
    Awad, L
    Jacques, C
    Herait, P
    LANCET, 1998, 352 (9138) : 1413 - 1418
  • [18] Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.
    Grothey, Axel
    Sobrero, Alberto F.
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Lenz, Heinz-Josef
    Yoshino, Takayuki
    Cihon, Frank
    Wagner, Andrea
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [19] Plasma arginine as a candidate predictive biomarker for response to immune checkpoint inhibition (ICI) in metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial
    Ma, Lucy Xiaolu
    Loree, Jonathan M.
    Jonker, Derek J.
    Kennecke, Hagen Fritz
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Chen, Eric X.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [20] COST-EFFECTIVENESS OF PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH BSC ALONE IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH WILD-TYPE (WT) KRAS TUMOR STATUS IN THE NETHERLANDS
    Graham, C. N.
    Borker, R.
    Oppe, M.
    Groot, C. A. Uyl-de
    Barber, B.
    Brogan, A. J.
    Amado, R. G.
    Peeters, M.
    Devercelli, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 134 - 134
12345